BMO Capital Reiterates Vertex (VRTX) at Outperform with $274 Price Target, Sees Good Odds of Proteinuria-based Approval of VX-147
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $274.00 price target on Vertex (NASDAQ: VRTX), following announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
